Evidence map›Paper›PMID 41451987›Full record

ArticleMicrobiology spectrum2026

Multidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project).

E Ramirez de Arellano, C López-Causapé, M Delgado-Valverde, F J Arroyo Muñoz, E Alemparte-Pardavila, J Arca-Suárez, I Ayestarán, J Calvo Montes, J Cañada-Garcia, S Garcia-Cobos and 19 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

E Ramirez de Arellano *Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-8276-9731
C López-Causapé *CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
M Delgado-ValverdeCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
F J Arroyo MuñozCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
E Alemparte-PardavilaServicio de Medicina Intensiva, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
J Arca-SuárezCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
I AyestaránCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
J Calvo MontesCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
J Cañada-GarciaCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
S Garcia-CobosCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
S García-FernándezCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
D Gijón CorderoCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
J J González-LópezCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
A Mir-CrosCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
X NuvialsCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
M Pérez-VázquezCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
A Pomares-de la PeñaUnidad de Gestión Clínica de Microbiología. Instituto Maimónides de Investigación de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
M Pampín-GarciaServicio de Microbiología & Instituto de Investigación Biomédica A Coruña (INIBIC), Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
C RiazzoUnidad de Gestión Clínica de Microbiología. Instituto Maimónides de Investigación de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
J Rodríguez-GómezCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
E Rojo-MolineroCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
P Ruiz-GarbajosaCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
C SorianoServicio de Medicina Intensiva, Hospital Universitario Ramón y Cajal, Madrid, Spain.
B Suberviola CañasServicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
B TaltavullCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
J Garnacho-MonteroCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
A Oliver PalomoCIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
J Oteo-IglesiasCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-3327-8263
MURAN-UCI Spanish group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant gram-negative bacteria (MDR-GNB) are one of the main challenges in intensive care units (ICUs), mainly extended-spectrum β-lactamase-producing

Indexed as

Drug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Negative Bacterial InfectionsAdultAgedAnti-Bacterial Agentsbeta-LactamasesCross InfectionFemaleHumansIncidenceIntensive Care UnitsMaleMicrobial Sensitivity TestsMiddle AgedMultilocus Sequence TypingAnti-Bacterial Agentsbeta-Lactamasescolonizationsgram-negative bacteriaICUsinfectionsmulti-resistance

Identifiers

PMID41451987
PMCPMC12889108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.